Financials data is unavailable for this security.
View more
Year on year Lincoln Pharmaceuticals Ltd grew revenues 13.76% from 5.10bn to 5.81bn while net income improved 27.99% from 728.99m to 933.05m.
| Gross margin | 51.92% |
|---|---|
| Net profit margin | 16.54% |
| Operating margin | 15.30% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, Lincoln Pharmaceuticals Ltd increased its cash reserves by 13.76%, or 6.95m. The company earned 632.17m from its operations for a Cash Flow Margin of 10.89%. In addition the company used 573.42m on investing activities and also paid 51.80m in financing cash flows.
| Cash flow per share | 54.56 |
|---|---|
| Price/Cash flow per share | 13.34 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 20.00% and 27.99%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.38% |
|---|---|
| Div growth rate (5 year) | 3.71% |
| Payout ratio (TTM) | 3.07% |
| EPS growth(5 years) | 13.85 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 27.40 |
More ▼
